vs
Side-by-side financial comparison of Axil Brands, Inc. (AXIL) and Kymera Therapeutics, Inc. (KYMR). Click either name above to swap in a different company.
Kymera Therapeutics, Inc. is the larger business by last-quarter revenue ($11.5M vs $8.1M, roughly 1.4× Axil Brands, Inc.). Axil Brands, Inc. runs the higher net margin — 8.7% vs -667.6%, a 676.3% gap on every dollar of revenue. On growth, Axil Brands, Inc. posted the faster year-over-year revenue change (5.2% vs -55.3%). Axil Brands, Inc. produced more free cash flow last quarter ($906.4K vs $-60.6M). Over the past eight quarters, Axil Brands, Inc.'s revenue compounded faster (12.1% CAGR vs 10.1%).
Axil Brands, Inc. is a U.S.-headquartered company that designs, manufactures and markets premium hearing protection products, audio enhancement devices and personal audio accessories. Its offerings include custom-fit earplugs, Bluetooth-enabled hearing buds for work, sports and leisure use, serving both consumer and professional segments across global markets.
Kymera Therapeutics is a clinical-stage biopharmaceutical company specialized in developing innovative targeted protein degradation therapies. It advances a diversified pipeline of drug candidates targeting previously undruggable proteins to address unmet medical needs in oncology, autoimmune and inflammatory diseases worldwide.
AXIL vs KYMR — Head-to-Head
Income Statement — Q2 FY2026 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $8.1M | $11.5M |
| Net Profit | $704.9K | $-76.6M |
| Gross Margin | 68.1% | — |
| Operating Margin | 11.1% | -736.8% |
| Net Margin | 8.7% | -667.6% |
| Revenue YoY | 5.2% | -55.3% |
| Net Profit YoY | 11.2% | -82.1% |
| EPS (diluted) | $0.09 | $-0.95 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $8.1M | — | ||
| Q3 25 | $6.9M | — | ||
| Q2 25 | $5.8M | $11.5M | ||
| Q1 25 | $6.9M | $22.1M | ||
| Q4 24 | $7.7M | $7.4M | ||
| Q3 24 | $5.9M | — | ||
| Q2 24 | $6.5M | $25.6M | ||
| Q1 24 | $6.5M | $10.3M |
| Q4 25 | $704.9K | — | ||
| Q3 25 | $334.3K | — | ||
| Q2 25 | $-245.6K | $-76.6M | ||
| Q1 25 | $576.7K | $-65.6M | ||
| Q4 24 | $633.7K | $-70.8M | ||
| Q3 24 | $-109.8K | — | ||
| Q2 24 | $49.5K | $-42.1M | ||
| Q1 24 | $781.1K | $-48.6M |
| Q4 25 | 68.1% | — | ||
| Q3 25 | 67.6% | — | ||
| Q2 25 | 70.0% | — | ||
| Q1 25 | 71.7% | — | ||
| Q4 24 | 71.1% | — | ||
| Q3 24 | 71.0% | — | ||
| Q2 24 | 71.5% | — | ||
| Q1 24 | 71.5% | — |
| Q4 25 | 11.1% | — | ||
| Q3 25 | 6.0% | — | ||
| Q2 25 | 0.8% | -736.8% | ||
| Q1 25 | 8.4% | -336.8% | ||
| Q4 24 | 8.7% | -1092.2% | ||
| Q3 24 | -2.4% | — | ||
| Q2 24 | 2.6% | -198.5% | ||
| Q1 24 | -1.6% | -562.2% |
| Q4 25 | 8.7% | — | ||
| Q3 25 | 4.9% | — | ||
| Q2 25 | -4.3% | -667.6% | ||
| Q1 25 | 8.3% | -296.7% | ||
| Q4 24 | 8.2% | -956.9% | ||
| Q3 24 | -1.9% | — | ||
| Q2 24 | 0.8% | -164.0% | ||
| Q1 24 | 12.1% | -472.0% |
| Q4 25 | $0.09 | — | ||
| Q3 25 | $0.04 | — | ||
| Q2 25 | $-0.03 | $-0.95 | ||
| Q1 25 | $0.07 | $-0.82 | ||
| Q4 24 | $0.08 | $-0.89 | ||
| Q3 24 | $-0.02 | — | ||
| Q2 24 | $0.11 | $-0.58 | ||
| Q1 24 | $0.04 | $-0.69 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $5.0M | $335.8M |
| Total DebtLower is stronger | $138.3K | — |
| Stockholders' EquityBook value | $11.1M | $971.5M |
| Total Assets | $16.2M | $1.1B |
| Debt / EquityLower = less leverage | 0.01× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $5.0M | — | ||
| Q3 25 | $4.1M | — | ||
| Q2 25 | $4.8M | $335.8M | ||
| Q1 25 | $4.7M | $90.0M | ||
| Q4 24 | $5.2M | $120.3M | ||
| Q3 24 | $4.1M | — | ||
| Q2 24 | $3.3M | $67.6M | ||
| Q1 24 | $4.9M | $93.5M |
| Q4 25 | $138.3K | — | ||
| Q3 25 | $139.2K | — | ||
| Q2 25 | $140.2K | — | ||
| Q1 25 | $141.0K | — | ||
| Q4 24 | $143.3K | — | ||
| Q3 24 | $144.3K | — | ||
| Q2 24 | $146.6K | — | ||
| Q1 24 | — | — |
| Q4 25 | $11.1M | — | ||
| Q3 25 | $10.2M | — | ||
| Q2 25 | $9.7M | $971.5M | ||
| Q1 25 | $9.7M | $786.2M | ||
| Q4 24 | $8.8M | $835.6M | ||
| Q3 24 | $7.9M | — | ||
| Q2 24 | $7.7M | $684.9M | ||
| Q1 24 | $8.8M | $711.2M |
| Q4 25 | $16.2M | — | ||
| Q3 25 | $15.4M | — | ||
| Q2 25 | $12.9M | $1.1B | ||
| Q1 25 | $13.0M | $918.3M | ||
| Q4 24 | $13.7M | $978.0M | ||
| Q3 24 | $11.4M | — | ||
| Q2 24 | $11.0M | $826.0M | ||
| Q1 24 | $12.7M | $868.3M |
| Q4 25 | 0.01× | — | ||
| Q3 25 | 0.01× | — | ||
| Q2 25 | 0.01× | — | ||
| Q1 25 | 0.01× | — | ||
| Q4 24 | 0.02× | — | ||
| Q3 24 | 0.02× | — | ||
| Q2 24 | 0.02× | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $934.8K | $-59.9M |
| Free Cash FlowOCF − Capex | $906.4K | $-60.6M |
| FCF MarginFCF / Revenue | 11.1% | -527.9% |
| Capex IntensityCapex / Revenue | 0.3% | 6.1% |
| Cash ConversionOCF / Net Profit | 1.33× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-250.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $934.8K | — | ||
| Q3 25 | $-739.2K | — | ||
| Q2 25 | $194.4K | $-59.9M | ||
| Q1 25 | $-169.9K | $-79.2M | ||
| Q4 24 | $1.0M | $-61.8M | ||
| Q3 24 | $897.3K | — | ||
| Q2 24 | $-336.6K | $-42.9M | ||
| Q1 24 | $-912.8K | $-39.6M |
| Q4 25 | $906.4K | — | ||
| Q3 25 | $-747.6K | — | ||
| Q2 25 | — | $-60.6M | ||
| Q1 25 | $-258.2K | $-79.6M | ||
| Q4 24 | $941.1K | $-62.7M | ||
| Q3 24 | — | — | ||
| Q2 24 | $-394.9K | $-47.6M | ||
| Q1 24 | $-922.1K | $-47.0M |
| Q4 25 | 11.1% | — | ||
| Q3 25 | -10.9% | — | ||
| Q2 25 | — | -527.9% | ||
| Q1 25 | -3.7% | -360.3% | ||
| Q4 24 | 12.2% | -848.3% | ||
| Q3 24 | — | — | ||
| Q2 24 | -6.1% | -185.7% | ||
| Q1 24 | -14.3% | -456.8% |
| Q4 25 | 0.3% | — | ||
| Q3 25 | 0.1% | — | ||
| Q2 25 | — | 6.1% | ||
| Q1 25 | 1.3% | 2.1% | ||
| Q4 24 | 0.9% | 12.7% | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.9% | 18.3% | ||
| Q1 24 | 0.1% | 72.0% |
| Q4 25 | 1.33× | — | ||
| Q3 25 | -2.21× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.29× | — | ||
| Q4 24 | 1.59× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -6.80× | — | ||
| Q1 24 | -1.17× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXIL
| Hearing Enhancement And Protection | $7.8M | 95% |
| Other | $378.9K | 5% |
KYMR
Segment breakdown not available.
